| 摘要 |
<p>The present technology relates to a method of treating cancer by sensitizing humantumours to DNA damaging therapies through activating FBXO32 expression.Transactivation of FBXO32 through the inhibition of EZH2, a histone methyltransferase,decreases p21 protein induction which results in the sensitization of human tumours tochemotherapy. The method further provides a prognostic method to determine if thecombination treatment would be effective.Figure 1E</p> |
